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Cost-BenefIt Model of VaryIng nexPlanon and otHer long-aCtIng 
reVersIBle ContraCePtIVe (larC) MetHods: UPtake CoMPared to tHe 
oral ContraCePtIVe PIll: Uk PersPeCtIVe
Praet C., D’Oca K.
Merck Sharp and Dohme Ltd, Hoddesdon, UK
Objectives: Cost is considered one of the major barriers to greater use of LARC 
(Long-Acting Reversible Contraceptive) methods, especially cost of treatment initia-
tion. However, when considering their contraceptive efficacy alongside cost of preg-
nancy, LARC methods are deemed by NICE to be more cost-effective than combined 
oral contraceptive pills even at one year of use. (NICE LARC CG30 2005). MethOds: 
A 3 year time-horizon cost-benefit model was developed to assess budgetary impact 
of increasing LARC uptake (implant, IUD, IUS and injectable) compared to the oral 
contraceptive pill, in UK women aged 16-49 who currently use the following con-
traceptives of interest: non-LARC method (defined as contraceptive pill only) or 
LARC methods (IUD, IUS, injectable, implant). A weighted-average price based on 
current market shares was calculated, for all contraceptive pills currently available 
in the UK. Increased uptake of any LARC method was offset against a reduction in 
contraceptive pill usage. Unintended pregnancies, based on typical failure rate, 
occurring with all treatments considered was taken into account. Results: Of 
approximately 14,750,000 women aged 16-49 in the UK, official statistics confirm 
37% use contraceptive methods of interest to our model. This proportion formed 
our cohort of approximately 5,500,000 UK women aged 16-49, which was followed 
over a 3 year time horizon. A 100% increase in uptake of each LARC method would 
lead to a 49% decrease in oral contraceptive pill uptake. Over a three year period 
this would save 374,794 unintended pregnancies, and elicit financial savings of 
£630,831,022, on which £54,098,847 is attributable to treatment costs (ingredient, 
consultations, removal/insertion costs) and £576,732,175 to the cost of unintended 
pregnancies (live birth, miscarriage, abortion, ectopic pregnancy). cOnclusiOns: 
The model projects that increasing LARC uptake will result in a significant reduc-
tion in the number of unintended pregnancies, with consequent savings to the 
NHS across the UK.
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Objectives: Our aim was to assess the costs and consequences of labour induction 
using misoprostol vaginal insert (MVI) compared with currently used technologies 
using a specifically developed user-friendly decision model developed for Austria, 
Poland, Romania, Russia and Slovakia. MethOds: The model was developed in 
Microsoft Office Excel and compares clinical and safety aspects like time to vaginal 
delivery, time to active labour, occurrence of cesarean delivery and adverse events 
of MVI with selected comparators. Efficacy and safety data were retrieved from tar-
geted literature review, conducted in the main medical databases. Country-specific 
information about costs and resource use was incorporated into the model. Local 
data were collected for each country via a specifically developed questionnaire. The 
model considered the hospital and public payer perspectives. The model gener-
ated results as an incremental difference between the total costs related to labour 
induction with MVI or a comparator. The threshold price of MVI was also calcu-
lated. Results: Local Key Opinion Leaders recommended the following compara-
tors: dinoprostone vaginal insert (DVI; Austria), dinoprostone vaginal tablets (Dtab; 
Austria, Slovakia), dinoprostone cervical gel (Dgel; Poland, Russia, Slovakia) and 
oxytocin (Austria, Poland, Romania, Russia). The hospital perspective was chosen 
as default (additionally the public payer perspective was adopted for 2 countries). 
The use of MVI in most scenarios is related to a reduction in time consumption of 
hospital staff and in the length of patients’ stay in hospital wards. MVI was less 
costly or marginally more expensive in 80% of cases. cOnclusiOns: Induction of 
labour with the use of MVI using a hospital perspective, brought savings in most 
countries and scenarios in comparison to other prostaglandins (DVI, Dtab, Dgel).
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Objectives: Herpes Zoster is a very painful and debilitating disease for which no 
satisfactory treatment exist. A vaccine is licensed in Europe for the prevention of 
Herpes Zoster (HZ) and postherpetic neuralgia (PHN) in adults aged ≥ 50 years and 
is recommended in France and UK. The objective of this study was to assess the 
cost-effectiveness of vaccination programs in people aged 65 years and over in 
Norway. MethOds: An existing European Markov cohort Model was adapted to 
the Norwegian health care setting. Health states considered are healthy, HZ, PHN, 
healthy post-HZ and death. HZ and PHN states are further split by pain severity 
(mild, moderate or severe). A vaccine efficacy durability model based on the pivotal 
trial data was included to simulate waning in the efficacy. The cost-effectiveness 
outcomes were assessed from both the third party payer and the societal perspec-
tive. First, analysis comparing a HZ vaccination policy for adults aged ≥ 65 years with 
a no vaccination policy was done. Then, analysis comparing vaccination policies 
of 5-years age class cohorts (from 65 to 100 years old) to a no vaccination policy 
were conducted. Input data were obtained from Norwegian sources whenever avail-
Objectives: Although the relationship between use of glucocorticoids (GC) and 
occurrence of adverse events (AE) is widely acknowledged, the estimation of risk 
size of specific AE is still imprecise. The aim of study was to quantify the incidence 
and economic cost of selected steroid-related AE in GC-users regardless of baseline 
chronic disease. MethOds: Review of the available data about the consequences 
of long-term use of oral GC (depending on prednisone or its equivalent dose and 
period of use) was conducted. From 162 full-text publications (10024 abstracts), 
four with mixed population and > 5 years median follow–up were valuable. Hip 
fracture (HFr), cataract (CAT) and diabetes mellitus (DM) were chosen as the com-
mon and most cost generating AE connected with oral GC treatment. A Markov 
model with a lifetime horizon (30 years) was developed to forecast incidence 
and health care cost of three regimen (non-GC, low dose GC < 2.5 mg, high dose 
GC > 7.5 mg). Direct medical costs were included in the analysis. Results: For a 
lifetime horizon the incidence of HFr, CAT and DM increased from 0.77% to 5.49%, 
23.48% to 91.04% and 12.34% to 17.02% (7.1, 3.9, 1.4 fold increase) respectively for 
comparison non-GC versus high dose GC. For selected cohort of 1,000 you need to 
treat 34, 2, 22 patients respectively (low dose GC instead of high dose GC) to prevent 
one additional case of HFr, CAT, DM. Shorter duration of steroid therapy (5 years) 
provide two Quality-Adjusted Life Months gained (per one patient) and leads to 
2,230, 35,460, 6,920 avoided cases of HFr, CAT, DM (per 100,000 cohort). The use 
of low-dose or non-GC is cost-effective strategy (total cost per patient 2,958 PLN, 
1,301 PLN, respectively) compared with high-dose GC (10,823 PLN). cOnclusiOns: 
Oral GC treatment can lead to dose-dependent increase in the risk of selected AE.
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Objectives: Some drugs increase risk for adverse effects in elderly patients. 
Accordingly, lists of potentially inappropriate medication (PIM) that should be 
avoided in elderly patients have been proposed. In 2010 an expert panel published 
a PIM list adapted to the German drug market (PRISCUS-list) which lists 83 inappro-
priate agents and their recommended surrogates. This study calculates the amount 
of drug reimbursement of PIM and the potential saving using appropriate surrogates 
recommended by the PRISCUS list from the perspective of statutory health insur-
ance (SHI). MethOds: Data was provided by AOK Research Institute (WIdO). Study 
material consists of a register extraction of the top 30 drugs (by sales) on PRISCUS-
list in 2009 for patients ≥ 65 years of the entire SHI-population. We calculated the 
percentage of sales and defined daily doses (DDD) for patients ≥ 65 compared to 
the total SHI-population. Costs for the recommended substitution were estimated 
by different scenarios. Results: In 2009, the proportion of the top 30 drugs on 
the PRISCUS-list that were prescribed to patients ≥ 65 was 58.2%. Sotalol was the 
drug with the largest proportion of DDD prescribed to patients ≥ 65 (92.9%). Drug 
reimbursement for the top 30 PIM medications prescribed to patients ≥ 65 were 
€ 305.7 million (54.3% of total reimbursement). Reimbursement for Solifenacin was 
highest with € 32.5 million. Prescription of the surrogates would lead to increasing 
costs for the German health care system. Those were calculated to range between 
€ 325.9 million and € 810.0 million. cOnclusiOns: This is the first study assessing 
the economic burden of PIM according to PRISCUS-list in Germany. The results show 
that a more appropriate medication for the elderly comes along with additional 
costs. For a final evaluation of relevance and economics of PIM, costs of adverse 
drug events caused by PIM and clinical feasibility of substitution have to be taken 
into consideration.
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Objectives: The primary objective of the study was the analysis of pharmaco-
economic expediency of administration of dydrogesterone (Duphaston®) for 
premenstrual syndrome (PMS) treatment in comparison with micronized pro-
gesterone (Utrogestan®). MethOds: The mathematical modeling with dydroges-
terone or micronized progesterone was applied in the study. For the calculation 
of the efficacy data of clinical trials were used. Costs were calculated on the basis 
of Russian prices (grls. rosminzdrav. ru). The model was constructed as follow-
ing: for each branch of the decision tree, cost and efficacy for a group of 100 
patients (female aged 18 – 45 years) and per patient were analyzed. Modeling 
duration was 3 months (therapy during three cycles). The cost-effectiveness ratio 
(CER) and incremental cost-effectiveness ratio (ICERs) were calculated. Results 
were evaluated to cost-effectiveness threshold. Efficiency was estimated on 
the basis of clinical trials (effectiveness). Calculation of cost included: the cost 
of drugs administration course; costs of consultative and diagnostic appoint-
ments of the gynecologist; the cost of inefficient therapy – costs of additional 
diagnostic examination. The comprehensive sensitivity analysis was per-
formed. Results: The cost of the total course of therapy with dydrogesterone 
was more expensive in comparison with micronized progesterone – 84,1 EUR 
against 82,6 EUR. Strategy of administration of dydrogesterone showed more 
efficiency in comparison with micronized progesteron (8% increase of effective-
ness). CER for dydrogesterone and micronized progesterone were 115.20 and 
127.07 respectively. The ICER was 18.75 Eur per patient that is much lower than 
a cost-effectiveness threshold in Russia (27922.8 EUR). The sensitivity analysis 
confirmed conclusions of the main scenario. cOnclusiOns: The strat-
egy of administration of dydrogesterone in PMS is economically expedient 
from the point of view of cost-effectiveness ratio. In addition, increase of effec-
tiveness was noted for use of dydrogesterone. The study was conducted at Abbott 
support.
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loss by 94, 76 and 87% respectively. The cost per case avoided would be 165 Euros, 
and cost per hospitalization avoided would be 1,639 Euros with implementation of 
universal vaccination. The cost per QALY saved would be 29,452 Euros and 20,453 
Euros from the health care and societal perspectives respectively. cOnclusiOns: 
RV5 is projected to avert substantial number of RGE hospitalizations and office vis-
its in Slovenia and would be considered a cost effective intervention. KEYWORDS: 
rotavirus vaccine, cost effectiveness, QALY.
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Objectives: Rotavirus gastroenteritis (RVGE) is one of the most frequent diseases in 
children less than 5 years old. Today, no recommendation for general rotavirus vac-
cination exists in Romania, which leads to a vaccination coverage rate of < 8%. We 
model whether the strategy of “Universal Mass Vaccination” should be cost-effective 
from the Social Health Insurance Fund (SHIF) perspective. MethOds: We adapted 
an already published simple model to estimate the cost-effectiveness of rotavirus 
vaccination in Romania. It helps identifying the drivers of the economic analysis in 
a birth cohort of 194,411 children (Romania 2012) followed over a period of 5 years. 
In the model, vaccine efficacy results from international clinical trials are combined 
with Romanian epidemiology and cost data from the SHIF perspective for 2012. The 
model assumes a theoretical vaccination rate of 100% and uses discount rates of 3% 
on costs and effects. Results are tested on their robustness using univariate sensitiv-
ity analysis. Results: The model predicts that a two-dose rotavirus vaccine could 
avoid around 82,581 mild, 51,328 moderate and 3,075 severe RVGE cases. Moderate 
and severe events are associated with physician visits and hospital stays respectively. 
These also lead to a total cost saving of € 2.4 million for indirect cost estimates. 
The main factors responsible for the savings are the reduction in hospital stays, in 
productivity losses of parents and in medical visits. Sensitivity analysis indicates 
the importance of good epidemiological data and cost numbers on productivity 
loss. cOnclusiOns: General vaccination against rotavirus could avoid many of the 
severe diarrhea events in children less than 5 years old in Romania. Depending on the 
price per course, the vaccination strategy will lead to societal cost gain.
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Objectives: Coffee contains over 1,000 distinct molecular compounds and is one 
of the most widely consumed beverages worldwide. Epidemiologic studies have 
shown an inverse relationship between coffee consumption and all-cause mortal-
ity. This analysis aims to assess the cost-effectiveness of coffee from a blended 
German consumer and payer perspective. MethOds: An existing decision-analytic 
model was adapted with German data. A cohort life-table analysis was developed 
to model life-years (LYs) of German coffee consumers vs. non-consumers over a 
lifetime horizon. Age- and gender-specific mortality rates were used to model sur-
vival outcomes. Relative risks of death by average coffee intake (cups/day) were 
obtained from a recent large, prospective cohort study. Cost were considered for 
cost per cup (home prepared and from a national sample of low and high-cost 
vendors) and for health care. Incremental analyses were conducted by cost, sex, 
and level of daily coffee consumption. Deterministic and probabilistic sensitivity 
analysis was performed. Results: Coffee increased undiscounted LYs in 1, 2-3, 
4-5, and 6+ cup/day male (0.65, 1.10, 1.33 and 1.10) and female (0.45, 1.21, 1.51, 1.41) 
consumers, respectively, versus non-consumers. ICERs per undiscounted LY gained 
were € 3,938/ € 7,047/ € 16,271 for males and € 5,514/ € 5,066/ € 13,537 for females, 
respectively, for 1, 2-3, and 4-5 cups/day consumption of home-prepared coffee; 
≥ 6 cups/day was strictly dominated. Consumption of 4-5 cups per day purchased 
from high-cost vendors was not cost-effective (male: € 168,780/ female: € 135,636). 
Results were consistent throughout the sensitivity analyses, whereas coffee effec-
tiveness in preventing death and coffee acquisition cost has the largest impact on 
ICERs. cOnclusiOns: In this analysis, coffee consumption was associated with 
increased LYs and was shown to be potentially cost-effective, especially if home-
prepared or purchased from low-cost vendors. Given the observational nature of the 
study data, further research is warranted to validate these findings.
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Cost-effeCtIVeness analysIs of sCreenIng syPHIlIs aMong  
Pregnant woMen
Chuluunbaatar E.
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Objectives: Maternal and congenital syphilis prevalence rates are currently rapidly 
increasing in Mongolia. On-Site screening and same-day treatment for syphilis 
in pregnancy prevents greater numbers of congenital syphilis and its complica-
tions. The Ministry of Health has been implementing on-site rapid screening test 
(RT) intervention and same day treatment approach for maternal syphilis with 
the contribution of the World Health Organization. Objective of the study was to 
understand the cost- effectiveness (CE) of screening antenatal syphilis using the 
RT strategy, to compare this intervention with RPR testing strategy. And in order to 
estimate CE we found out maternal syphilis prevalence. MethOds: Ingredients-
based cost data and epidemiological data were collected retrospectively from the 
pregnancy medical records. Decision analysis was used to estimate the incremental 
CE of on-site PT compared to the current practice, off-site PRP/TPHA. Descriptive 
analysis has done for prevalence of syphilis, and economic analysis has done to 
calculate costs. Stability of cost-effectiveness ratios were evaluated by the univariate 
sensitivity analysis. Results: With antenatal syphilis prevalence of 3.0% (1.46% 
in urban and 5.7% in sub-urban area), the cost effectiveness was US$ 14.60/DALY 
able. Results: The strategy of vaccinating people over 65 yo showed incremen-
tal cost-effectiveness ratios of 41,467€ /QALY gained from a payer perspective and 
40,733€ /QALY from a societal perspective. The analysis by age group showed that 
the ICER is age-dependent, the lowest ICER (30,780€ /QALY in both perspectives) 
having been found in the cohort 70-74 years old. In sensitivity analyses data on 
the duration of PHN, utilities and vaccine efficacy duration showed a major impact 
on the results. cOnclusiOns: Our cost-effectiveness analysis shows that a HZ 
vaccination policy for adults aged ≥ 65 years in Norway could be cost-effective and 
provide substantial public health benefits in the Norwegian health care system.
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Objectives: To analyze the cost effectiveness of surgical management of stress 
urinary incontinence (SUI) in women with single-incision mini-sling (SIMS) com-
pared with tension-free vaginal obturator (TVT-O) MethOds: A cost-effectiveness 
analysis based on the results of interventions performed with TVT-O (2005-2008) 
and SIMS (2008-2011) in women with a diagnosis of SUI was performed. The clini-
cal effectiveness was defined as an objective cure at 12 months (pad-test < 1 g/h). 
A perspective of the hospital payer was adopted; therefore, only direct health care 
costs (diagnostic and surgical procedures, medical devices, medications, hospital 
stay times and staff) were included. CI95% of total cost was estimated by boot-
strapping; later, different sensitivity analyses were conducted Results: Procedures 
were carried out in 81 women (44 in the SIMS group and 37 in the TVT-O). A small 
difference (6.7%) in clinical effectiveness was observed in favour of SIMS, however, 
it was not statistically significant (SIMS: 93.2% and TVT-O: 86.5%). The total annual 
cost per patient with SIS was lower (2,059€ ; CI95%: 1,914-2,285) than with TVT-O 
(2,821€ ; CI95%: 2,661-2,997), showing a statistically significant cost saving of 762€ 
(CI95%: 516-987). In the base case, the probability of SIMS is less costly than TVT-O 
was 100%. The sensitivity analysis showed that the cost determinant was the length 
of the hospital stay, observing that an equivalent cost was only achieved if there 
was no cause for any hospital stay with TVT-O. cOnclusiOns: The use of single-
incision mini-sling is associated with an comparable clinical effectiveness but with 
a 762€ per patient reduction of the average annual cost, compared to tension-free 
vaginal obturator. Therefore, the results suggest that, over a post-operative period 
of twelve months, tension-free tape single-incision mini-sling is a dominant alter-
native to tension-free vaginal obturator because of a lower cost and a comparable 
effectiveness.
PIH27
a Cost-effeCtIVeness analysIs of dIfferent tyPes of laBor for 
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Objectives: To assess cost, clinical outcomes and cost-effectiveness of different 
types of labor in singleton pregnancies. MethOds: A decision model was used 
to compare vaginal labor, induced labor and planned cesarean section. All data 
were taken from the Book of Labor from the University Hospital for Gynecology 
and Obstetrics “Narodni Front” in Serbia, for labors conducted during one month 
period in 2011. Successful delivery, (i. e. labor that began up to 42 gestation weeks, 
without maternal mortality and the newborn Apgar scores greater than or equal 
to seven in the first and fifth minute of life) was considered as the outcome of the 
cost effectiveness analysis. To test the robustness of this definition probabilistic 
sensitivity analysis was performed. Results: From a total of 667 births, vaginal 
labor was conducted in 98 cases, induced vaginal in 442, while planned caesarean 
section was performed 127 times. Emergency caesarean section as a complication 
was much higher in the vaginal labor cohort compared to the induced vaginal 
cohort (OR = 17.374, 95% CI: 8.522 to 35.418, p < 0.001). The least costly type of labor 
was induced vaginal labor: average cost 461 euro, with an effectiveness of 98.17%. 
Both, vaginal and planned cesarean labor, were dominated by the induced labor. 
The results were robust. cOnclusiOns: Elective induction of labor was associated 
with the lowest cost compared to other types of labor, with favorable maternal and 
neonatal outcomes.
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Objectives: To assess the potential impact of universal vaccination with RV5 on 
health care burden and costs associated with rotavirus gastroenteritis (RGE) among 
a hypothetical birth cohort of 21,938 Slovenian children in their first five years of 
life MethOds: A Markov model was used to evaluate the cost per quality-adjusted-
life-year (QALY) and public health impact of vaccination with RV5 from the health 
care payer and societal perspectives. The base case assumes three dose coverage 
rate of 94% at 2, 4 and 6 months among the vaccinated, the remaining receiving 1 
or 2 doses. In the absence of universal vaccination 819 hospitalizations and 3,276 
office visits were projected to occur in the first 5 years of life. RGE associated costs 
include direct and indirect costs associated with parental work loss. The efficacy 
of RV5 in reducing health care resource utilization is based on the results of the 
Rotavirus Efficacy and Safety Trial (REST). Results: A universal RV5 vaccination 
program is projected to reduce hospitalizations, office visits and parental work 
